Summary by Futu AI
On September 6, 2024, SciSparc Ltd., a clinical-stage pharmaceutical company, and Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, announced the publication of an international patent application for a novel MDMA-based combination treatment. This collaboration aims to enhance the safety and efficacy of treatments for mental health disorders and addictions by combining MDMA with N-Acylethanolamines, including Palmitoylethanolamide (PEA). SciSparc's CEO, Oz Adler, highlighted the significance of the collaboration in addressing FDA concerns regarding MDMA safety. The patent application is part of a broader research initiative between the two companies, which has resulted in thirteen patents filed to date. SciSparc is also involved in drug development programs for various central nervous system disorders and owns a controlling interest in a subsidiary selling hemp seed oil products. Clearmind's focus is on developing psychedelic-based compounds for health problems such as alcohol use disorder and holds nineteen patent families with 29 granted patents.
